Tarsus Pharmaceuticals, Inc.

NasdaqGS:TARS Stock Report

Market Cap: US$2.7b

Tarsus Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:TARS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Mar 26SellUS$2,364,904Bobak AzamianIndividual34,603US$69.42
19 Mar 26SellUS$439,566Jeffrey S. FarrowIndividual6,430US$69.42
19 Mar 26SellUS$892,528Aziz MottiwalaIndividual13,056US$69.42
19 Mar 26SellUS$772,444Seshadri NeervannanIndividual11,324US$69.42
19 Mar 26SellUS$78,204Elizabeth YeuIndividual1,144US$69.42
19 Mar 26SellUS$850,417Bryan WahlIndividual12,440US$69.42
19 Mar 26SellUS$839,070Dianne WhitfieldIndividual12,274US$69.42
08 Sep 25SellUS$1,545,612William LinkIndividual27,116US$57.00

Insider Trading Volume

Insider Buying: TARS insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of TARS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,397,9082.9%
VC/PE Firms3,600,0007.47%
Hedge Funds5,908,17912.3%
Institutions37,256,81777.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 80.38% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.37%
Deep Track Capital, LP
3,600,000US$223.0m19.8%3.86%
8.26%
BlackRock, Inc.
3,552,612US$220.1m-6.28%no data
7.78%
RTW Investments, LP
3,346,025US$207.3m0.32%1.99%
5.96%
Paradigm Biocapital Advisors LP
2,562,154US$158.7m0%3.53%
5.21%
Janus Henderson Group plc
2,240,963US$138.8m16.1%0.05%
4.34%
Morgan Stanley
1,868,677US$115.8m-5.27%0.01%
4.09%
Vanguard Capital Management, LLC
1,760,541US$109.1m0%no data
3.98%
Jennison Associates LLC
1,712,124US$106.1m-23.2%0.06%
2.98%
Assenagon Asset Management S.A.
1,280,194US$79.3m13.5%0.09%
2.76%
Tang Capital Management, LLC
1,188,624US$73.6m0%3.36%
2.61%
Geode Capital Management, LLC
1,121,091US$69.5m18.3%no data
2.27%
State Street Global Advisors, Inc.
978,212US$60.6m5.29%no data
2.2%
Bank of America Corporation
948,071US$58.7m128%0.01%
2.15%
Driehaus Capital Management LLC
926,125US$57.4m-21%0.25%
2.07%
Bobak Azamian
891,412US$55.2m3.68%no data
1.96%
Lord, Abbett & Co. LLC
842,313US$52.2m-1.56%0.14%
1.91%
Medical Strategy GmbH
821,962US$50.9m0%3.23%
1.84%
D. E. Shaw & Co., L.P.
791,146US$49.0m28.6%0.04%
1.7%
FMR LLC
733,270US$45.4m13.3%no data
1.69%
Frazier Life Sciences Management, LP
728,644US$45.1m0%1.16%
1.33%
Invesco Ltd.
570,110US$35.3m-34.4%0.01%
1.31%
Millennium Management LLC
564,579US$35.0m383%0.02%
1.27%
ClearBridge Investments, LLC
545,351US$33.8m7.76%0.02%
1.19%
The Toronto-Dominion Bank
510,253US$31.6m0%0.04%
1.16%
Nomura Investment Management Business Trust
499,853US$31.0m-14.5%0.04%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 14:20
End of Day Share Price 2026/06/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tarsus Pharmaceuticals, Inc. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jenna DavidnerBarclays
Jason Matthew GerberryBofA Global Research
Andrea NewkirkGoldman Sachs